Nevertheless, certain targeting CD30 and CD7 CAR-T cell therapies have yielded rather promising treatment outcomes in T-cell lymphoma (11–13), whose effectiveness provides a glimmer of optimism within the otherwise arduous terrain of T-cell malignancy treatment and justifies further exploration and optimization. The gene discussed is CD7; the disease is T-cell non-Hodgkin lymphoma.